Diseases of the developing world are exacerbated by the lack of stable social, economic, political, and medical infrastructures. Only 11% of global health expenditure is targeted to the 84% of the world’s population that suffers from 93% of the global disease burden. What often results is malnutrition, inadequate medical interventions, and a lack of basic public health measures including access to clean water, good sewage, housing, education and vaccinations. In the late 1990s, infrastructures were created to better address diseases that affect the poor. Over 20 public-private partnerships were chartered to address various aspects of these diseases and to develop better diagnostic assays, pharmaceuticals, and vaccines. This forum features various stakeholders who will weigh in on opportunities for the biotech industry to make a difference in this arena.
- List effective best practices of public-private partnerships with biopharmaceutical companies
- Describe ways industry may play a role in these public-private partnerships
- Discuss how to effectively engage governments/institutions from low income settings
Ability Level: All
Session ID: 1977